@techreport{oai:kanazawa-u.repo.nii.ac.jp:00034574,
 month = {May},
 note = {免疫組織化学とfluorescence in situ hybridization (FISH) を使って475例の胃癌を検索した結果、51 例にHER2遺伝子増幅を持った癌細胞を認め、21 例(42%)でその増幅は不均一であった。Multiplex ligation-dependent probe amplification (MLPA)及びFISH では、HER2とMYCの同一腫瘍細胞内での増幅が8例に、同じくMYCとFGFR2またはEGFRの同時増幅がそれぞれ1 例にみられた。一方、HER2とEGFR 、HER2/FGFR2 , HER2/MET/FGFR2の同一腫瘍内で異なる細胞上での増幅がそれぞれ7例、1例、1例にみられた。この結果は、胃癌に対する、個別化分子標的療法を行う上で重要であると結論された。, By combined analysis of immunohistochemistry and fluorescence in situ hybridization (FISH) on 475 formalin-fixed paraffin-embedded tissue, 51 gastric adenocarcinoma with HER2-amplified cancer cells. The heterogeneity of HER2 amplification, if defined as the existence of less than 50% of cancer cells positive for ERBB2 amplification, the 21 tumors (42%) would be heterogeneous. The combined analysis of multiplex ligation-dependent probe amplification (MLPA) and FISH revealed that, co-amplification in individual cells of HER2 and MYC were found in 8 tumors and MYC/FGFR2, and MYC/EGFR in a case respectively. On the other hand, co-amplification of HER2/EGFR in 7, HER2/FGFR2 in one tumor and HER2/MET/FGFR2 in a tumor, however the respective genes were mutually exclusively amplified. In conclusion, the semi-comprehensive information of amplification status of HER2 and other genes obtained by the combined study of MLPA and FISH may be useful to plan individualized molecular target therapy against gastric cancers., 研究課題/領域番号:22590310, 研究期間(年度):2010–2012, 出典：研究課題「分子標的療法の導入を視野に入れた胃癌におけるHER2異常の包括的検討」研究課題番号22590310
（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） 
（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-22590310/22590310seika/）を加工して作成, 金沢大学医薬保健研究域医学系},
 title = {分子標的療法の導入を視野に入れた胃癌におけるHER2異常の包括的検討},
 year = {2013}
}